Acurx Pharmaceuticals, Inc. · NASDAQ:ACXP
Acurx Pharmaceuticals — World Antimicrobial Resistance Conference 2023
15 slides from Acurx Pharmaceuticals's conference presentation, Sep 7, 2023
Slide 1: First of a New Class of Antibiotics Targeting Priority Pathogens
First of a New Class of Antibiotics Targeting “Priority Pathogens” Preparing for the Next Pandemic: Antimicrobial Resistance Robert J. DeLuccia Executive Chairman World Antimicrobial Resistance Conference September 7, 2023
Slide 2: Disclosure: Forward-Looking Statements
Disclosure Acurx Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, development plans, regulatory activities, anticipated milestones, product candidate benefits, competitiv
Slide 3: AMR: Global Challenge
AMR: GLOBAL CHALLENGE Acurx We must prepare our public health systems to fight multiple threats, simultaneously. Because antimicrobial resistance will not stop, we must meet the challenge. Now is the time to address our current antimicrobial-resistant threats, while simultaneously preparing for unkn
Slide 4: Company Mission and Key Publications
Acurx Company Mission and Key Publications § Develop new class of antibiotics for difficult-to-treat bacterial infections THE UNTOLD STORY UNFOLDING § Lead DNA pol IIIC Inhibitor discovered by Wright/Brown, Professors Emeritus, UMass; Acurx acquired in 2018* § First of a new class of antimicrobials
Slide 5: Acurx Snapshot
Acurx Snapshot Acurx Novel Mechanism of Action: §Previously unexploited scientific target §Lead pol IIIC Inhibitor discovered by Wright/Brown Professors Emeriti, UMass; Acurx acquired in 20181 §Innovation criteria2: ü New chemical class ü New target (Gram+; now clinically validated) ü New MOA (Uniqu
Slide 6: Ibezapolstat: Phase 2a Success
ACX-362E Highlights Disclosures Acurx Ibezapolstat: Phase 2a Success § Patients with mild to moderate CDI treated with orally administered ibezapolstat given 450mg twice daily for 10 days § All 10 patients (100%) met the study's primary and secondary efficacy endpoints of Initial Cure and Sustained
Slide 7: Ibezapolstat Phase 2b Clinical Trial Design
Ibezapolstat Phase 2b Clinical Trial Design Acurx Segment 2A Open-Label Phase 3 Segment 2B Double-Blind Non-inferiority to Active-Controlled Acurx Snapshot § Phase 2 dose (450 mg BID) § n = 20 vancomycin ibezapolstat 450 mg BID Phase 3 § 6 sites (US) (n = 32), 10 days ~ N patients - TBD § After firs
Slide 8: Management Expects Ph2b success. Why?
Acurx Management Expects Ph2b success. Why? Factors that will provide confidence in successful outcomes of future clinical trials: § Invitro potency vs C. difficile (+100x concentration needed) § Excellent human safety profile § High human fecal concentrations (>100-fold above MIC50 in patient sampl
Slide 9: Systemic GPSS Antibiotic: Program Highlights
Systemic GPSS™ Antibiotic: Program Highlights Acurx Systemic Pol IIIC Inhibitor Program: Oral and IV formulations to target systemic treatment of Staphylococcus, Streptococcus and Enterococcal infections, including MRSA, VRE, and other resistant G+ bacterial infections; WHO/CDC Priority Pathogen Lis
Slide 10: Systemic GPSS Antibiotic: Program Goal / Progress
Systemic GPSS Antibiotic: Program Goal / Progress Acurx ™ § Hit-to-Lead testing of >500 novel compounds resulted in significant improvements in: § Cytotoxicity, solubility, plasma protein binding § In vitro & in vivo safety § Oral and IV efficacy in mouse infection models including in neutropenic mi
Slide 11: LUMC Collaboration: High-Throughput IC50 Assay and 3D Crystal Structures
LUMC Collaboration: Developing High-Throughput IC50 Assay Acurx and 3D Crystal Structures of Acurx compounds bound to Pol IIIC IC50 Inhibition Assay Multiple 2D Images: VRE Pol IIIC Early 3D Image Map: VRE Pol IIIC 11 11
Slide 12: Experienced Senior Executive Management
Experienced Senior Executive Management Acurx § David P. Luci, CPA, Esq., CEO, Former CEO Dipexium Pharmaceuticals (Nasdaq:DPRX); Abeona Therapeutics, MacroChem, Bioenvision. Raised capital in several public offerings and private placements; sold 3 public companies from “C” suite § Robert J. DeLucci
Slide 13: Management Team
Management Team Acurx Michael Silverman, MD, FACP: Acurx Medical Director (Independent consultant) >30 years’ experience clinical research/product development; KPMG Health Care Consulting; Biopure Corp, Sandoz, Sterling-Winthrop (Kodak-Sanofi) and clinical practice of medicine Xiang Yu, PhD, Pre-Cli
Slide 14: Scientific / Corporate Advisors
Scientific / Corporate Advisors Acurx SCIENTIFIC § Jack H. Dean, Ph.D., Former Director, Worldwide Pre-Clinical Research at Sanofi; Research Professor, Univ of Arizona (Pharmacology & Toxicology) § Richard Ellison, MD, Professor of Medicine, UMass Medical School (Microbiology § Kevin Garey, PharmD*,
Slide 15: No new classes of antibiotics discovered or approved in decades
No new classes of antibiotics discovered or approved in decades Have foresight NOW not to repeat history with inadequate pipeline of novel antibiotics to treat infections caused by MRSA and other Gram+ organisms Please visit our website: www.acurxpharma.com ACXP: Nasdaq Contact: Bob DeLuccia 914-949
Acurx Pharmaceuticals — World Antimicrobial Resistance Conference 2023 on 6ix